Status:

UNKNOWN

Trinity™ BIOLOX Delta™ CoC THR Multi-center Study

Lead Sponsor:

Corin

Conditions:

Osteoarthritis

Avascular Necrosis

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

To demonstrate the safety and effectiveness of the Trinity™ BIOLOX delta™ Ceramic-on-Ceramic Total Hip System in comparison to the Trinity™ Acetabular Hip System,which is FDA cleared for use in the U....

Detailed Description

The clinical research results for the Trinity™ BIOLOX delta™ Ceramic-on-Ceramic Total Hip System will be compared to the control device Clinical success is based upon Harris Hip Scores to evaluate fu...

Eligibility Criteria

Inclusion

  • preoperative Harris Hip Score of ≤ 70.
  • preoperative Harris Hip Total Pain score of at least moderate.
  • diagnosed with non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis, rheumatoid arthritis, correction of functional deformity, developmental hip dysplasia (DDH) and congenital hip dysplasia (CDH).
  • pain rating of none or slight and are at least 12 months post-operative in the contralateral hip, if applicable.
  • have sufficient femoral and acetabular bone stock as determined by a clinician, and are suitable to receive implants as confirmed by x-rays.

Exclusion

  • have a nutritional problem (protein, calorie, or vitamin/mineral deficiency) that may impair wound healing mechanisms as determined by the clinician /investigator.
  • have a neurological disorders which may interfere or adversely affect gait, balance, or weight bearing (e.g. muscular dystrophy, multiple sclerosis).
  • diagnosed with metabolic disorders (e.g. osteomalacia), which may impair bone metabolism.
  • diagnosed systemic disease that would affect their welfare or the overall outcome of study (i.e. Paget's disease, renal osteodystrophy)
  • immunologically suppressed.
  • receiving systemic steroid therapy, excluding inhalers, within 3 months prior to surgery.
  • diagnosed Charcot's disease, metastatic or neoplastic disease.
  • evidence of active infections that may spread to other areas of the body (e.g. osteomyelitis, pyogenic infection of the hip joint, overt infection, untreated urinary tract infection, etc.).
  • presence of a previous prosthetic hip replacement device (any type, including surface replacement arthroplasty, endoprosthesis, etc.) in the hip joint to be operated.
  • previous Girdlestone procedure (resection arthroplasty) or surgical fusion of the hip to be operated.
  • diagnosed with systemic lupus erythematosus, pigmented villonodular synovitis, juvenile rheumatoid arthritis or other diagnoses with autoimmune etiology.
  • diagnosed with osteoporosis or as evidenced on a DEXA scan for males over 75 or females over 65 years of age (within the last 12 months).
  • require structural bone grafts in order to support the prosthetic component(s) or to shape the bone to receive the implant(s).
  • have acute femoral neck fracture or hip fractures.
  • have an above the knee amputation of the contralateral and/or ipsilateral leg.
  • have an existing total hip arthroplasty in the contralateral hip with a pain rating of 3 or more on a scale of 0 to 10, where 0 is "no pain" and 10 is "severe pain".
  • have had a total hip arthroplasty in the contralateral hip within the past 12 months.
  • have previously received a metal-on-metal hip arthroplasty.
  • have a highly communicable disease or diseases that may limit follow-up (e.g. immunocompromised conditions, hepatitis, active tuberculosis, etc.).
  • have any known sensitivity to device material.
  • Females who are pregnant.
  • Patients who are prisoners.

Key Trial Info

Start Date :

December 1 2012

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2021

Estimated Enrollment :

342 Patients enrolled

Trial Details

Trial ID

NCT01921309

Start Date

December 1 2012

End Date

December 1 2021

Last Update

March 11 2021

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

Arkansas Specialty Orthopaedics

Little Rock, Arkansas, United States, 72205

2

Denver Hip and Knee, Inc.

Parker, Colorado, United States, 80134

3

Connecticut Joint Replacement Institute (CJRI)

Hartford, Connecticut, United States, 06105

4

Mayo Clinic Jacksonville

Jacksonville, Florida, United States, 32224